Typologie d'actualités: Group NMR of Biomolecules

A butterfly peptide to combat resistant fungi

A promising avenue for better crop protection and perhaps even for treating certain diseases, as reported by CNRS Chimie.

Fungal infections represent a major global health problem, with increasing resistance to currently available antifungal molecules. Targeting glucosylceramides (GlcCer), which are functionally essential glycosphingolipids present in fungal membranes, represents a promising strategy for the development of new antifungal agents.

GlcCer are associated with the antifungal activity of certain antimicrobial peptides found in plants and insects, known as defensins. The ETD151 peptide, optimised from butterfly defensins, is active against a range of fungal pathogens of interest to human health and agriculture. For example, the researchers have previously shown that ETD151 induces a multifaceted mechanism of action on Botrytis cinerea, a multi-resistant phytopathogenic fungus used here as a model (Aumer et al. 2020).

This multifaceted mechanism of action makes ETD151 a promising candidate for combating fungal resistance. The researchers took up the challenge of identifying its molecular target. They showed that the ETD151 peptide binds at the molecular level to GlcCer and localises preferentially to the membrane, where it induces various toxic effects. Identifying its molecular target and understanding the mode of action of ETD151 opens up new prospects for human health and crop protection.

Reference :
O. Kharrat, Y. Yamaryo-Botté, R. Nasreddine, S. Voisin, T. Aumer, B.P.A. Cammue, J. Madinier, T. Knobloch, K. Thevissen, R. Nehmé, V. Aucagne, C. Botté, P. Bulet, & C. Landon.
The antimicrobial activity of ETD151 defensin is dictated by the presence of glycosphingolipids in the targeted organisms.
Proc. Natl. Acad. Sci. U.S.A. (2025) 122 (7) e2415524122, https://doi.org/10.1073/pnas.2415524122.

Research on glioma (brain tumor) carried out at the CBM highlighted by CNRS Chimie

The use of different original NMR methods (MRI, 1H HR-MAS, 2D liquid NMR) made it possible to characterize a glioma model established in adult Drosophila and to reveal the therapeutic potential of a serotonin receptor for the treatment of these cancers.

Read the CNRS Chimie article.

Read the "Actualité chimique" article n° 492, 2024, February

Gliomas account for 50% of brain cancers and therefore constitute the most common brain tumors. Molecular alterations involved in adult gliomas have been identified and mainly affect tyrosine kinase receptors with amplification and/or mutation of the epidermal growth factor receptor (EGFR) and its associated signaling pathways. Several targeted therapies have been developed but current treatments remain ineffective for glioblastomas, the most severe forms. Thus, it is a priority to identify new pharmacological targets. Here, we used a Drosophila glioma model in adult, to characterize metabolic disturbances associated with glioma and assess the consequences of the serotonin 5-HT7 receptor expression on glioma development. First, by using in vivo Magnetic Resonance Imaging, we have shown that expression of the constitutively active forms of EGFR and PI3K in adult glial cells induced enlargement of brains. Then, we explored altered cellular metabolism by using High-Resolution Magic Angle Spinning NMR and 1H-13C Heteronuclear Single Quantum Coherence solution state. Discriminant metabolites identified highlight rewiring of metabolic pathways in glioma, and associated cachexia phenotypes. Finally, the expression of 5-HT7R in this model attenuates phenotypes associated with glioma development (brain enlargement and cachexia).

Article :
An adult Drosophila glioma model to highlight metabolic dysfunctions and evaluate the role of the serotonin 5-HT7 receptor as a potential therapeutic target.
Bertrand M, Szeremeta F, Hervouet‐Coste N, Sarou-Kanian V, Landon C, Morisset-Lopez S, Decoville M
The FASEB Journal. 2023 37:e23230. doi:10.1096/fj.202300783RR

CBM PhD students have talent!

Ons Kharrat, from the "NMR of Biomolecules" group, received one of the 3 prizes for the best oral communication at the GDR MuFoPAM days which took place from October 19 to 21, 2022.
This prize was awarded to him by the company Genepep (https://www.genepep.com/accueil/).

Elodie Villalonga, from the "Cell signaling and neurofibromatosis" group, won one of the 2 prizes for the best oral communication
and
Valentin Beauvais, from the group “Dysregulation of autophagy during inflammation due to HIV”, received one of the poster prizes at the 34th Biotechnocentre conference which took place on October 20 and 21, 2022.